Litcius/Paper detail

Tertiary RNA Folding-Targeted Drug Screening Strategy Using a Protein Nanopore

Dong-Hwa Lee, Sohee Oh, Kyung‐Eun Lim, Boah Lee, Gwan‐Su Yi, Young‐Rok Kim, Ki‐Bum Kim, Chong‐Kil Lee, Seung‐Wook Chi, Mi‐Kyung Lee

2021Analytical Chemistry20 citationsDOI

Abstract

Bacterial riboswitch RNAs are attractive targets for novel antibiotics against antibiotic-resistant superbacteria. Their binding to cognate metabolites is essential for the regulation of bacterial gene expression. Despite the importance of RNAs as therapeutic targets, the development of RNA-targeted, small-molecule drugs is limited by current biophysical methods. Here, we monitored the specific interaction between the adenine-sensing riboswitch aptamer domain (ARS) and adenine at the single-molecule level using α-hemolysin (αHL) nanopores. During adenine-induced tertiary folding, adenine-bound ARS intermediates exhibited characteristic nanopore events, including a two-level ionic current blockade and a ∼ 5.6-fold longer dwell time than that of free RNA. In a proof-of-concept experiment, tertiary RNA folding-targeted drug screening was performed using a protein nanopore, which resulted in the discovery of three new ARS-targeting hit compounds from a natural compound library. Taken together, these results reveal that αHL nanopores are a valuable platform for ultrasensitive, label-free, and single-molecule-based drug screening against therapeutic RNA targets.

Topics & Concepts

RiboswitchChemistryRNAAptamerNanoporeDrug discoveryFolding (DSP implementation)Small moleculeComputational biologyBiochemistryBiophysicsNanotechnologyNon-coding RNAMolecular biologyGeneBiologyMaterials scienceElectrical engineeringEngineeringNanopore and Nanochannel Transport StudiesRNA and protein synthesis mechanismsRNA modifications and cancer
Tertiary RNA Folding-Targeted Drug Screening Strategy Using a Protein Nanopore | Litcius